2015 Oflos ANNUAL MEETIN6 Meetine MATERIALS OCTOBER
Total Page:16
File Type:pdf, Size:1020Kb
2015 OflOS ANNUAL MEETIN6 MEETINe MATERIALS OCTOBER 16, 2015 COLUMBUS, OHIO SOCIETY BOARD MEMBERS 2015 ANNUAL MEETING Slobodan Stanisic, MD President The Christ Hospital Medical Specialists II, Cincinnati, Ohio Scott Blair, MD Trustee Columbus Oncology Associates, Columbus, Ohio Cheryl Skinner, MD President Elect Lebanon Hematology Oncology, Lebanon, Ohio Charles Bane, MD Secretary Dayton Physicians LLC, Dayton, Ohio David Fishman, MD Trustee David J. Fishman, MD, Inc., Cleveland, Ohio Nashat Gabrail, MD Trustee Gabrail Cancer Center, Canton, Ohio David Brown, MD Trustee Toledo Clinic Cancer Centers, Toledo, Ohio Ohio ^ Hematology Oncology^ iSociety SPONSORS 'isto' CardlnalHealth Essential to care' 2015 Annual Meeting Friday, October 16, 2015 Nationwide Hotel & Conference Center 100 Green Meadows Drive South Lewis Center, OH 43035 AGENDA 8:30-10:00 Meeting Registration 9:00-10:00 Reimbursement and Biosimilars Michelle Weiss Weiss Oncology Consulting 10:00-10:30 Break\Exhibits 10:30-11:30 ICD-10: Issues in Implementation Jean Stevens, RHIT, CCS-P, AHIMA approved ICD-10 Trainer 11:30-12:30 Lunch\Exhibits 12:30-1:30 The High Cost of Hope Mary Jameson, MBA Dayton Physicians LLC 1:30-2:30 MyCGS Juan Lumpkin CGS Administrators 2:30-2:45 Break 2:45-3:30 MyCare Ohio: Serving Ohio’s Dual Eligibles Christi Pepe Ohio Department of Medicaid Ohio Hematology Oncology ^Society 2015 ANNUAL MEETING MEMBERS SPONSORS and EXHIBITORS MEMBERS, SPONSORS, AND EXHIBITORS AMAG Pharmaceuticals OHOS Bronze Member 100 Hayden Avenue Exhibitor Lexington, MA 02421 Phone: 617-498-7700 Websites: www.amagpharma.com and www.feraheme.com Company contacts: Chris Riedel criedel@amagpharma.com Ryan Weisenseel weisenseel@amagpharma.com AMAG Pharmaceutcials is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeuitic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the FDA to market Feraheme™ (ferumoxytol) Injection for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company or product information please visit www.amagpharma.com. Amgen OHOS Silver Member One Amgen Center Drive Exhibitor Thousand Oaks, CA 91320 Website: www.amgen.com Company contact: Lisa Dunn dunn@amgen.com Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Astellas Oncolgy Inc. OHOS Silver Member 1 Astellas Way Exhibitor Three Parkway North Northbrook, IL 60062 Website: www.astellas.us Company contact: Curtis Sosnowski, Sr. Access & Reimbursement Manager – Great Lakes 248-705-1675 (cell) 248-922-9097 (office) curtis.sosnowski@astellas.com Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.us. AstraZeneca OHOS Silver Member 1800 Concord Pike Exhibitor Wilmington DE 19850 Phone: 1-800-236-9933 Website: www.astrazeneca-us.com Company contacts: Jeff Catalfino jeff.catalfino@astrazeneca.com Joyce Bohl Joyce.bohl@astrazeneca.com Brian Jenkins Brian.Jenkins@astrazeneca.com Brad Kranson Bradley.kranson@astrazeneca.com Samantha Terry – Field Reimbursement Manager TerryS@medimmune.com AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. For patients and physicians, we provide medicines for some of the world’s most serious diseases. For the people who pay for health care, we work to make sure that our medicines offer real value for money. For our employees, we provide a culture in which they can feel appreciated, energized and rewarded for their contribution. For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business. We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Bayer Healthcare OHOS Silver Member 100 Bayer Blvd. Whippany, NJ 07981 Phone: 866-NEXAVAR (866-639-2827) Website: www.bayerpharma.com Company contact: Dale Gray, Field Reimbursement Manager 502-553-3256 dale.gray@bayer.com About Oncology at Bayer - Bayer is committed to delivering Science for a Better Life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated. Bristol Myers Squibb Oncology OHOS Gold Member 777 Scudders Mill Road Sponsor Plainsboro, New Jersey 08543-4500 Exhibitor Phone: 609-897-2000 Website: www.bms.com Company contacts: Roger Pawar roger.pawar@bms.com Marcelo Molina marcelo.molina@bms.com Cary Harris cary.harris@bms.com Linda Martens Linda.martens@bms.com Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and C, HIV/AIDS and rheumatoid arthritis. Cardinal Health OHOS Silver Member 7000 Cardinal Place Sponsor Dublin, OH 43017 Exhibitor Phone: 614-757-5000 Website: www.cardinal.com Company contact: Steve Brenner, Director, Sales, Oncology Specialty Solutions 614-551-3408 Steve.brenner@cardinalheath.com Cardinal Health Specialty Solutions is a business of Cardinal Health, a Fortune 21 healthcare services company headquartered in Dublin, Ohio. With more than 30,000 employees worldwide, Cardinal Health is one of the largest healthcare companies in the world. Cardinal Health Specialty Solutions puts intelligence into action by offering solutions that help healthcare professionals, payors and the pharmaceutical and biotech industries in specialty healthcare, solve tomorrow's problems today. We help our customers alleviate day-to-day administrative burdens, optimize business functions and utilize innovative solutions that drive business forward. Celgene OHOS Gold Member 86 Morris Avenue Sponsor Summit, NJ 07901 Exhibitor Phone: 908-673-9000 Website: www.celgene.com Company contacts: Keith D. Jenkins (Senior Regional Account Manager) 240-215-7779 KJenkins@celgene.com Andrew Sawyer (Regional Sales Director, Ohio Valley) asawyer@celgene.com Allyson Dusza (Hematology Oncology Consultant) 614-562-0873 adusza@celgene.com Alan Huber (Hematology Oncology Consultant) 419-351-3089 ahuber@celgene.com Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Eisai, Inc. OHOS Bronze Member 100 Tice Blvd. Exhibitor Woodcliff Lake, NJ 07677 Phone: 888-793-4724 Website: www.eisai.com Company contact: Ron Corpora, Director, National Reimbursement 330-929-2041 ron_corpora@eisai.com As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai